Send to

Choose Destination
J Hepatol. 2011 Nov;55(5):1063-8. doi: 10.1016/j.jhep.2011.01.052. Epub 2011 Feb 25.

Validation of the "Metroticket" predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma.

Author information

New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland 1023, New Zealand.



The "Metroticket" prognostic model for survival post liver transplant for hepatocellular carcinoma (HCC) was developed from a European cohort of patients with predominantly alcoholic liver disease and hepatitis C-related HCC. The aim of this study was to evaluate the prognostic value of the Metroticket in an independent cohort of patients with predominantly HBV-related HCC, in an Asia-Pacific transplant programme.


All patients listed for HCC at the New Zealand Liver Transplant Unit (NZLTU) between January 1998 and November 2009 were included. For each patient, the predicted 3 and 5 year post-transplant survival score was calculated using the Metroticket model ( The observed and predicted survivals were compared.


Ninety-five patients with HCC were listed, 82 were transplanted (40 with HBV) and 13 delisted for progression. Predicted survival calculated by the Metroticket model based on pre-transplant radiological data (n = 82) was 76.3% and 69.7% at 3 and 5 years, respectively, while the observed survival was 83% (49/59) and 74% (35/47), respectively. Of the 40 patients with HBV, observed survivals were 84% (26/31) and 80% (20/25) at 3 and 5 years, compared with 80% (23/28) and 69.6% (16/23), respectively, for the 42 patients without HBV. On intent to treat analysis, survival after listing was 73.8% (95% CI 62.7-82.1) at 3 years and 69.1% (53.7-78.2%) at 5 years. AFP level was associated with vascular invasion.


The Metroticket calculator incorporating pre-transplant radiological Staging was an accurate predictor of post-transplant survival in a cohort of predominantly HBV-related HCC.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center